{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:15:51Z","timestamp":1789881351255,"version":"4.0.1"},"reference-count":70,"publisher":"Japanese Circulation Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2009]]},"DOI":"10.1253\/circj.cj-09-0573","type":"journal-article","created":{"date-parts":[[2009,10,23]],"date-time":"2009-10-23T06:00:45Z","timestamp":1256277645000},"page":"1973-1982","source":"Crossref","is-referenced-by-count":36,"title":["Mechanisms of Remodelling A Question of Life (Stem Cell Production) and Death (Myocyte Apoptosis)"],"prefix":"10.1253","volume":"73","author":[{"given":"Roberto","family":"Ferrari","sequence":"first","affiliation":[{"name":"Chair of Cardiology, University Hospital of Ferrara"},{"name":"Fondazione Salvatore Maugeri, IRCCS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Ceconi","sequence":"additional","affiliation":[{"name":"Chair of Cardiology, University Hospital of Ferrara"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Campo","sequence":"additional","affiliation":[{"name":"Chair of Cardiology, University Hospital of Ferrara"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Cangiano","sequence":"additional","affiliation":[{"name":"Chair of Cardiology, University Hospital of Ferrara"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Cavazza","sequence":"additional","affiliation":[{"name":"Chair of Cardiology, University Hospital of Ferrara"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Secchiero","sequence":"additional","affiliation":[{"name":"Sezione di Anatomia Umana University Hospital of Ferrara"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Tavazzi","sequence":"additional","affiliation":[{"name":"GVM Hospitals of Care and Research, Cotignola"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1038\/35025196"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80043-4"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.17.10261"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling: Concepts and clinical implications: A consensus paper from an international forum on cardiac remodelling. J Am Coll Cardiol 2000; 35: 269-282.","DOI":"10.1016\/S0735-1097(99)00630-0"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Eaton LW, Bulkley BH. Expansion of acute myocardial infraction: Its relationship to infarct morphology in a canine model. Circ Res 1981; 49: 80-88.","DOI":"10.1161\/01.RES.49.1.80"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hochman JS, Bulkley BH. Expansion of acute myocardial infarction; an experimental study. Circulation 1982; 65: 1446-1450.","DOI":"10.1161\/01.CIR.65.7.1446"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Weisman H, Bush DE, Mannisi JA, Bulkley BH. Global cardiac remodeling after acute myocardial infarction: A study in the rat model. Am J Cardiol 1985; 5: 1355-1362.","DOI":"10.1016\/S0735-1097(85)80348-X"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. McKay RG, Pfeffer MA, Pasternak RC, Markis JE, Come PC, Nakao S. Left ventricular remodeling after myocardial infarction: A corollary to infarct expansion. Circulation 1986; 74: 693-702.","DOI":"10.1161\/01.CIR.74.4.693"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Hutchins GM, Bulkley BH. Infarct expansion extension: Two different complications of acute myocardial infarction. Am J Cardiol 1978; 41: 1127-1133.","DOI":"10.1016\/0002-9149(78)90869-X"},{"key":"10","unstructured":"10. Anversa P, Olivetti G, Capasso JM. Cellular basis of ventricular remodeling. JACC 2000; 35: 569-582."},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi289"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000136813.89036.21"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Gaudron P, Eilles C, Kugler I, Ertl G. Progressive left ventricular dysfunction and remodeling after myocardial infarction. Circulation 1993; 87: 755-763.","DOI":"10.1161\/01.CIR.87.3.755"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. White HD, Norris RM, Brown MA, Brandt PWT, Whitlock RML, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from endomyocardial infarction. Circulation 1987; 76: 44-51.","DOI":"10.1161\/01.CIR.76.1.44"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Weber KT, Brilla CG. Pathological hypertrophy and the cardiac interstitium: Fibrosis and the renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-1865.","DOI":"10.1161\/01.CIR.83.6.1849"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.35.1.509"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA. Apoptosis in the failing human heart. N Engl J Med 1997; 336: 1131-1141.","DOI":"10.1056\/NEJM199704173361603"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Anderson KR, Sutton MG, Lie JT. Histopathological types of cardiac fibrosis in myocardial disease. J Pathol 1978; 128: 79-85.","DOI":"10.1002\/path.1711280205"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Villareal FJ, Kim NN, Ungab GD, Printz MP, Dillmann WH. Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation 1993; 88: 2849-2861.","DOI":"10.1161\/01.CIR.88.6.2849"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.15.8801"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80729-1"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1038\/378386a0"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Sheng Z, Pennica D, Wood WI, Chien KR. Cardiotrophin-1 displays early expression in the murine heart tube and promotes cardiac myocyte survival. Development 1996; 122: 419-428.","DOI":"10.1242\/dev.122.2.419"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Wollert KC, Chien KR. Cardiotrophin-1 and the role gp130-dependent signaling pathways in cardiac growth and development. J Mol Med 1997; 75: 492-501.","DOI":"10.1007\/s001090050134"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-08-0734"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.15.1.797"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118747"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.4.2161"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Perik PJ, de Korte MA, van Veldhuisen DJ, Gietema JA, Sleijfer DT, de Vries EG. Cardiotoxicity associated with the use of trastuzumab in breast cancer patients. Expert Rev Anticancer Ther 2007; 7: 1763-1771.","DOI":"10.1586\/14737140.7.12.1763"},{"key":"30","unstructured":"30. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity. J Clin Oncol 2006; 23: 2900-2902."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819-823.","DOI":"10.1056\/NEJM198409273111303"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Chidsey C, Braunwald E, Morrow AG, Mason DT. Myocardial norepinephrine concentrations in man. N Engl J Med 1963; 269: 653-658.","DOI":"10.1056\/NEJM196309262691302"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. McClure S, Carunana L, Davie AP, Goldthorp S, McMurray JJ. Cohort study of plasma natriuretic peptides for identifying left ventricular systolic dysfunction in primary care. BMJ 1998; 317: 516-519.","DOI":"10.1136\/bmj.317.7157.516"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92930-R"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Packer M, Bristow MR, Cohn JN, for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-1355.","DOI":"10.1056\/NEJM199605233342101"},{"key":"36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)04440-2"},{"key":"37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)11181-9"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. CIBIS Investigators and Committee. A randomized trial of betablockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765-1773.","DOI":"10.1161\/01.CIR.90.4.1765"},{"key":"39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)80008-6"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al; MOCHA investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2807-2816.","DOI":"10.1161\/01.CIR.94.11.2807"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Basu S, Senior R, Raval U, van der Does R, Bruckner T, Lahiri A. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction: A placebo-controlled randomized trial. Circulation 1997; 96: 183-191.","DOI":"10.1161\/01.CIR.96.1.183"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: The PRECISE trial [Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise]. Circulation 1996; 94: 2793-2799.","DOI":"10.1161\/01.CIR.94.11.2793"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, et al. Safety and efficacy of carvedilol in severe heart failure: The US Carvedilol Heart Failure Study Group. J Card Fail 1997; 3: 173-179.","DOI":"10.1016\/S1071-9164(97)90013-0"},{"key":"44","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)00012-0"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, et al. Effect of long-term enalapril on cardiac structure and function in patients with left ventricular dysfunction. Circulation 1995; 91: 2573-2581.","DOI":"10.1161\/01.CIR.91.10.2573"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Lechat P, Escolano S, Golmard JL. Prognostic value of bisoprololinduced hemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1997; 96: 2197-2205.","DOI":"10.1161\/01.CIR.96.7.2197"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: Critical role of the AT1 receptor subtype. Circ Res 1993; 73: 413-423.","DOI":"10.1161\/01.RES.73.3.413"},{"key":"48","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90541-W"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Ollivier JP, Bouchet VA. Prospects for cardioreparation. Am J Cardiol 1992; 70: 27-36C.","DOI":"10.1016\/0002-9149(92)91355-8"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: Response to angiotensin II and aldosterone. J Mol Cell Immunol 1994; 26: 809-820.","DOI":"10.1006\/jmcc.1994.1098"},{"key":"51","unstructured":"51. Sheehan JP, Seelig MS. Interactions of magnesium and potassium in the pathogenesis of cardiovascular disease. Magnesium 1984; 3: 301-314."},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669-677.","DOI":"10.1056\/NEJM199209033271001"},{"issue":"8875","key":"53","first-page":"821","volume":"342","year":"1993","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction: Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333: 1670-1676.","DOI":"10.1056\/NEJM199512213332503"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Beckwith C, Munger MA. Effect of angiotensin-converting enzyme inhibitors on ventricular remodeling and survival following myocardial infarction. Ann Pharmacother 1993; 27: 755-766.","DOI":"10.1177\/106002809302700617"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310.","DOI":"10.1056\/NEJM199108013250502"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. The SOLVD Investigators. The effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325: 293-302.","DOI":"10.1056\/NEJM199108013250501"},{"key":"58","doi-asserted-by":"publisher","DOI":"10.1001\/jama.273.18.1450"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Iraqi W, Rossignol P, Angioi M, Fay R, Nuée J, Ketelslegers JM, et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: Insights From the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) Study. Circulation 2009; 119: 2471-2479.","DOI":"10.1161\/CIRCULATIONAHA.108.809194"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435.","DOI":"10.1056\/NEJM198706043162301"},{"key":"61","unstructured":"61. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilation after anterior myocardial infarction. N Engl J Med 1987; 317: 787-792."},{"key":"62","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)95428-0"},{"key":"63","unstructured":"63. Sutton M St John, Keane MG. Reverse remodelling in heart failure with cardiac resynchronisation therapy. Heart 2007; 93: 167-171."},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Chakir K, Daya SK, Aiba T, Tunin RS, Dimaano VL, Abraham TP, et al. Mechanisms of enhanced beta-adrenergic reserve from cardiac resynchronization therapy. Circulation 2009; 119: 1231-1240.","DOI":"10.1161\/CIRCULATIONAHA.108.774752"},{"key":"65","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00551-3"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moyé LA, Dagenais GR, et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction: The protective effects of captopril. Circulation 1994; 89: 68-75.","DOI":"10.1161\/01.CIR.89.1.68"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. PEAMI Investigators. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodelling and clinical outcome: Results of the PREAMI Study. Arch Intern Med 2006; 166: 659-666.","DOI":"10.1001\/archinte.166.6.659"},{"key":"68","doi-asserted-by":"publisher","DOI":"10.1253\/circj.72.1336"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Agnoletti L, Curello S, Bachetti T, Malacarne F, Gaia G, Comini L, et al. Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: Role of tumor necrosis factor-α. Circulation 1999; 100: 1983-1991.","DOI":"10.1161\/01.CIR.100.19.1983"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Dufour C, Corcione A, Svahn J, Haupt R, Poggi V, Béka'ssy AN, et al. TNF-α and IFN-y are overexpressed in the bone marrow of Fanconi anaemia patients and TNF-α suppresses erythropoiesis in vitro. Blood 2003; 102: 2053-2059.","DOI":"10.1182\/blood-2003-01-0114"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/circj\/73\/11\/73_CJ-09-0573\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T19:21:25Z","timestamp":1634066485000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/circj\/73\/11\/73_CJ-09-0573\/_article"}},"subtitle":["A Question of Life (Stem Cell Production) and Death (Myocyte Apoptosis)"],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":70,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-09-0573","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009]]}}}